News and Trends 25 Apr 2017 Novartis Negotiates its Way into the US Migraine Market …drug candidates directed at Alzheimer’s and migraine, under which Amgen received the rights for the U.S., Canada, and Japan, while Novartis was left in charge of the residual markets. Now,… April 25, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 10 Mar 2017 Galapagos finds a Partner to Boost its Pipeline with Drug Combinations …trials two drug combinations identified through its platform, one in Phase III for the rare disease Charcot-Marie-Tooth type 1A, the other in Phase II for Alzheimer’s and Phase I for… March 10, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 26 Mar 2018 Attacking an Ancient Virus Slows Multiple Sclerosis in Phase II …to treat disorders of the central nervous system, since similar endogenous retroviruses have been linked to cases of schizophrenia, ALS and Alzheimer’s. Images via HelloRF Zcool, Kateryna Kon /Shutterstock… March 26, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Top biotech grants and campaigns …Alliance The Global Fund Mental health Brain & Behavior Research Foundation Mental Health Research UK One Mind Neurology Alzheimer’s Association American Epilepsy Society CurePSP Dana Foundation Epilepsy Foundation Huntington’s Disease… June 20, 2024 - 2 minutesmins - By Aurore Michelin Share WhatsApp Twitter Linkedin Email
Best in Biotech 26 Dec 2017 Interviews, Reviews and Tops: Our Best Biotech Articles from 2017 …Alzheimer’s Disease has been a graveyard for biotechs with repeated failures, but one company that is getting some traction is TauRx. Tim Earle is its COO/CBO, and as “the commercial… December 26, 2017 - 6 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 30 May 2023 Pancreatic cancer microbiome discovery holds treatment hope …neurological diseases such as Alzheimer’s disease and Parkinson’s disease. “Our bacteriophage-based new drug is undoubtedly a ‘first-in-concept’ drug that can effectively control various immune-related diseases. Therefore, we will continue to… May 30, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Sep 2017 Belgian Biotech Teams Up With Lundbeck to Collaborate on Drug Discovery …a candidate, HTL0016878, which has entered the clinic to treat Alzheimer’s. Before that, Heptares Therapeutics had already been busy, buying G7 Therapeutics for €11M to get hold of its technology… September 26, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Best in Biotech 10 Jun 2025 Pushing biotech forward in France: 18 companies to know about …neurodegenerative disorders like Alzheimer’s and Parkinson’s diseases. Cilcare is also conducting the SAPHIR observational study to explore the link between hearing impairments and neurodegenerative diseases. The study aims to develop… June 10, 2025 - 16 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jan 2024 Is the biotech industry poised for recovery in 2024? …FDA nods were high-profile therapies like Eli Lilly’s obesity drug Zepbound and Eisai and Biogen’s Alzheimer’s treatment Leqembi. Furthermore, 2023 saw the FDA greenlighting five gene therapies, including a landmark… January 8, 2024 - 5 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 23 Aug 2022 Company’s 3D microchip gives mechanistic insights into human brain …diseases of the brain that pose a high burden for our society, for example Alzheimer’s and epilepsy. Scientifically, Accura-3D is super exciting, because it will allow us to peek deeper… August 23, 2022 - 5 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 22 Feb 2017 Meet these 5 Awesome Biotechs from Barcelona at BIO Europe Spring 2017 …is being tested in 3 Phase I trials to treat dementia (including Alzheimer’s and Parkinson’s), multiple sclerosis and Huntington’s. Minoryx Therapeutics is committed to finding innovative treatments for life-threatening… February 22, 2017 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Best in Biotech 5 Mar 2024 Fourteen biotech companies with market caps exceeding $100 billion …billion. This deal enhances their neuroscience portfolio by adding KarXT, a novel treatment for schizophrenia and Alzheimer’s disease psychosis, with potential launches and trials outlined for the coming years. This… March 5, 2024 - 18 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email